激活转录因子3是一种抗瘤基因,与生长分化因子15协同作用,以调节人类膀癌细胞生长
Syue-Ting Chen1, Kang-Shuo Chang2, Wei-Yin Lin3
1Department of Anatomy, College of Medicine, Chang Gung University, Taoyuan, Taiwan; Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan; Department of Urology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.
Biomedical journal
|June 28, 2024
概括
激活转录因子3 (ATF3) 是膀癌中的抗瘤基因,与GDF15.15正相关. 低ATF3/GDF15水平表明预后不佳,ATF3调节瘤生长和入侵.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 人类膀中激活转录因子3 (ATF3) 的作用尚不清楚.
- 这项研究调查了ATF3在人类膀癌中的表达,功能和调节.
研究的目的:
- 探索ATF3在人类膀癌中的表达和功能.
- 确定ATF3在膀癌中的调节机制.
- 评估ATF3/GDF15作为膀癌的预后标志物.
主要方法:
- 基因表达分析 (免疫块,RT-qPCR,记者检测).
- 在体外和体内测试细胞增殖,入侵和瘤发生 (Ki67,殖民地形成,Matrigel入侵,异种移植研究).
- 对TCGA数据库进行生物信息分析,以查找ATF3,GDF15,临床病理特征和生存率之间的相关性.
主要成果:
- 在膀癌组织中,ATF3充当抗瘤基因,其表达与GDF15正相关.
- 低ATF3/GDF15比率是膀癌患者无进展生存的独立预后因素.
- ATF3的过度表达抑制了扩散和入侵,而ATF3的淘汰增强了它们;ATF3通过反循环调节GDF15.
结论:
- ATF3 是一种在膀癌中由甲胺升调的抗瘤基因.
- ATF3/GDF15比率作为膀癌的潜在负预后标志物,得到了生物信息学和基于细胞的发现的支持.
相关概念视频
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Somatic to iPS Cell Reprogramming
2.2K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.2K


